Spruce Biosciences, Inc.
SPRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001683553
No open-market purchases or sales by Spruce Biosciences, Inc. insiders were filed in the last 90 days; 65 institutions reported holding it in 13F filings for Q2 2026, worth $116.3M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Spruce Biosciences, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 40 | 41 | +1 |
| Shares | 18.9M | 20.1M | +1.23M (+6.5%) |
| Value | $313.2M | $225.3M | −$87.9M (−28.1%) |
New holders (5)
Institutions that held Spruce Biosciences, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 2,046,958 | $22.9M | 0.41% |
| Caas Capital Management LP | 92,412 | $1.04M | 0.06% |
| Alps Advisors Inc | 30,726 | $344.0K | 0.00% |
| Alyeska Investment Group, L.P. | 19,413 | $218.0K | 0.00% |
| Two Sigma Investments, LP | 11,975 | $134.0K | 0.00% |
Sold out (4)
Institutions that held Spruce Biosciences, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| PFM Health Sciences, LP | 489,631 | $8.13M |
| ArrowMark Colorado Holdings LLC | 128,000 | $2.13M |
| Credit Suisse AG | 23,899 | $397.0K |
| Bank of Montreal | 216 | $3.00K |